Use of TGF-.beta.3, to prevent or retard fistula closure following glaucoma filtration surgery
US5449671A · kind A · utility
0Cited by
3References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 29, 1993 |
| Grant date | Sep 12, 1995 |
| Priority date | — |
| Expiry date | Sep 29, 2013 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/1841
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The intraocular use of TGF-.beta..sub.3 in connection with glaucoma filtration surgery is described. A composition containing TGF-.beta..sub.3 is applied to the surgical site to suppress the production and/or alter the composition of extracellular matrix synthesized by fibroblasts at the surgical site, and thereby reduce the formation of scar tissue and consequent impairment of the outflow of aqueous humor through a fistula created during the surgery.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.